Omega-3 fatty acid supplements not helpful for CVD prevention, JAMA reports

Article

Treatment with omega-3 polyunsaturated fatty acids to prevent cardiovascular disease has been controversial. See what the overall results of one recent meta-analysis and review say about the issue.

Treatment with omega-3 polyunsaturated fatty acids (PUFAs) to prevent cardiovascular disease (CVD) has been controversial. A recent meta-analysis and review showed that overall, omega-3 PUFA supplementation did not lower the risk of CVD, according to data published in the September 12 issue of JAMA.

Evangelos C. Rizos, MD, PhD, and colleagues conducted a literature review and included data from 20 randomized studies of 68,680 patients, who received omega-3 as supplements or through dietary counseling. All but 2 trials were based on omega-3 supplementation with a mean omega-3 dose of 1.51 g per day. In 10 studies, the omega-3 dose was 1 g or greater per day. Median treatment duration was 2 years and the maximum was 6.2 years. In most cases, omega-3 PUFAs were administered for secondary CVD prevention, the authors noted.

“Overall, omega-3 PUFA supplements were not statistically significantly associated with a reduced all-cause mortality (RR=0.96; 95% CI, 0.91-1.02; P=.17),” the authors said. In the all-cause mortality review, 17 studies were included for a total of 6,295 events in a group of 63,279 participants.

In a review of 13 studies, 3,480 cardiac deaths occurred in a group of 56,407 participants. Again, omega-3 supplements were not helpful, showing no statistically significant association for supplementation and cardiac death (RR=0.91; 95% CI, 0.85-0.98; P=.01), the article noted.

The authors also found that omega-3 supplementation did not reduce the rates of sudden death, according to 7 studies of 41,751 patients and 1,030 events (RR=0.87; 95% CI, 0.75-1.01; P=.06). Supplementation did not reduce the risk of myocardial infarction, which included 13 studies of 53,875 patients (RR=0.89; 95% CI, 0.76-1.04; P=.14), or stroke, which included data from 9 studies of 52,589 patients (RR=1.05; 95% CI, 0.93-1.18; P=.47).

“Our findings do not justify the use of omega-3 as a structured intervention in everyday clinical practice or guidelines supporting dietary omega-3 PUFA administration,” the authors concluded.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.